Acute postinfectious pityriasis rubra pilaris as a cutaneous manifestation in COVID‐19: a case report and its dermoscopic features

Kadylak, Damian; Barańska‐Rybak, Wioletta

doi:10.1111/jdv.17424

Cited by 11 publications

(18 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To the best of our knowledge, only two cases of PRP have been reported following COVID‐19 infection. 5 , 6 Presence of temporal association and thorough evaluation has led us to propose that it is a potential trigger for the disease.…”

Section: Figurementioning

confidence: 99%

Acute postinfectious type III pityriasis rubra pilaris as a cutaneous manifestation in COVID‐19: Decoding a possible trigger!!

Arora

Mohta

Ghiya

et al. 2022

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Section: Figurementioning

confidence: 99%

Acute postinfectious type III pityriasis rubra pilaris as a cutaneous manifestation in COVID‐19: Decoding a possible trigger!!

Arora

Mohta

Ghiya

et al. 2022

J of Cosmetic Dermatology

View full text Add to dashboard Cite

“…Consequently, following Lladó et al [13], who reported post-COVID vaccination PRP for the first time, 15 further cases including the present patient have now been published [4][5][6][7][8][9][10][11][12][13] (Table 1). Regarding post-COVID-19 infection-related PRP, we identified four previously reported cases, including a case reported by us of a patient who developed PRP after SARS-CoV-2 vaccination and a concomitant breakthrough infection [5,[18][19][20]. Moreover, Margo et al [21] reported PRP-like cases with atypical histopathology such as an interface dermatitis.…”

Section: Discussionmentioning

confidence: 97%

First Onset of Pityriasis Rubra Pilaris following SARS-CoV-2 Booster Vaccination: Case Report and Review of the Literature

Gambichler¹,

Scheel²,

Arafat³

et al. 2022

Dermato

View full text Add to dashboard Cite

There is increasing evidence of adverse events associated with the use of COVID-19 vaccines. Here, we report a case of the SARS-CoV-2-vaccination-related onset of pityriasis rubra pilaris (PRP) and provide an analysis of previously reported cases in the medical literature. A 67-year-old male presented with a 1-year history of histopathologically proven PRP that first developed 14 days after receiving a COVID-19 booster vaccination. Skin symptoms improved under ustekinumab medication after unsuccessful previous treatment approaches using systemic corticosteroids, brodalumab, and risankizumab. Among the published cases of post-COVID vaccination PRP, 12 (75%) males and 4 (25%) females were reported. The median age of the reported patients was 59 years. In 10 out of 16 patients (62.5%), PRP was diagnosed after the first vaccine dose, in 4 (25%) after the second dose, and in 2 of 15 patients (12.5%) after the third dose. The median time between COVID-19 vaccination and the onset of PRP was 9.5 days (range: 3–60 days). The majority of patients required systemic treatment, including systemic retinoids and methotrexate. PRP might be a rare adverse event after COVID-19 vaccination, particularly affecting older males. Even though most reported patients with COVID-19-vaccination-related PRP could be successfully treated with PRP standard medications, therapy refractory cases may also occur. Thus, clinicians must be aware of this rare but potentially severe complication.

show abstract

“…Известно, что вирусы, такие как вирус герпеса и ВИЧ, могут стать причиной развития красного волосяного отрубевидного лишая Девержи. Однако описания случаев развития этого заболевания в связи с инфекцией SARS-CoV-2 в доступной нам литературе мало [5,6]. В связи с разнообразием кожных проявлений, сопровождающих течение коронавирусной инфекции, рекомендуется проводить дифференциальную диагностику заболеваний кожи при помощи иммуногистохимических исследований на выявление пролиферации иммунокомпетентных клеток.…”

Section: Discussionunclassified

Pityriasis rubra pilaris (Devergie's disease) in a COVID-19 patient

Okladnikova

Kotova

Khorzhevskii

et al. 2022

Vestnik dermatologii i venerologii

View full text Add to dashboard Cite

Pityriasis rubra pilaris (Devergie's disease) is an idiopathic, papulosquamous inflammatory dermatosis characterized by progressive erythrodermia. The etiology of the disease is unknown, and most cases occur sporadically. Viral infections, impaired vitamin A metabolism, medications, autoimmune reactions, and malignancies are most common triggering factors. The diagnosis of Devergie's disease is based on the clinical manifestations of the disease and the results of a skin histological examination. The present paper discusses a clinical case of pityriasis rubra pilaris that occurred in a COVID-19, 40-year-old woman. For the purpose of differential diagnosis of pitiriasis with atopic dermatitis, erythrodermic form of psoriasis, generalized form of urticaria, it is necessary to perform immunohistochemical studies to identify the proliferation of immunocompetent cells. Based on the described clinical case, it seems possible to recommend testing for SARS-CoV-2 if a patient has Devergie's disease against the background of fever and intoxication syndrome.

show abstract

Acute postinfectious pityriasis rubra pilaris as a cutaneous manifestation in COVID‐19: a case report and its dermoscopic features

Cited by 11 publications

References 6 publications

Acute postinfectious type III pityriasis rubra pilaris as a cutaneous manifestation in COVID‐19: Decoding a possible trigger!!

Acute postinfectious type III pityriasis rubra pilaris as a cutaneous manifestation in COVID‐19: Decoding a possible trigger!!

First Onset of Pityriasis Rubra Pilaris following SARS-CoV-2 Booster Vaccination: Case Report and Review of the Literature

Pityriasis rubra pilaris (Devergie's disease) in a COVID-19 patient

Contact Info

Product

Resources

About